🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Gan & Lee Pharmaceuticals clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Gan & Lee Pharmaceuticals as lead sponsor. Synced 26 Sep 2026
25Current trials
9Recruiting now
8Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Gan & Lee Pharmaceuticals is the lead sponsor of 25 current clinical trials in our China register. 9 are recruiting patients now. The most common phase is Phase 3. The drugs named most often in its trials are GZR18, GZR4 and GZR102. The most-studied condition is Diabetes.

ClinicalTrials.gov trials by status

  • Recruiting936%
  • Not yet open832%
  • Active, closed832%

Trials by phase

  • Phase 31352%
  • Phase 11040%
  • Phase 228%
01

Clinical trials sponsored by Gan & Lee Pharmaceuticals

25 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Phase IIIb Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin
NCT07165223 · ClinicalTrials.gov ↗ · Diabetes
Drug: GZR4
Phase 3 Recruiting 2025-10 China
Bioequivalence Study of GZR18 Injection Before and After CMC Change
NCT07355738 · ClinicalTrials.gov ↗ · Obesity&T2D
Phase 1 Recruiting 2026-01 China
A Clinical Study to Evaluate the Efficacy, Tolerability, and Safety of Bempedoic Acid
NCT06780410 · ClinicalTrials.gov ↗ · Primary Hyperlipidemia
Phase 3 Recruiting 2024-12 China
Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Liver Insufficiency and Normal Liver Function
NCT07144098 · ClinicalTrials.gov ↗ · Obesity/Overweight
Drug: GZR18
Phase 1 Recruiting 2025-08 China
Study of Pharmacokinetics and Safety of GZR18 Injection in Subjects With Renal Impairment and Normal Renal Function
NCT07141030 · ClinicalTrials.gov ↗ · Obesity/Overweight
Drug: GZR18
Phase 1 Recruiting 2025-04 China
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects
NCT07150975 · ClinicalTrials.gov ↗ · Obesity/Overweight in Adult
Phase 3 Recruiting 2025-09 China
Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection
NCT07128888 · ClinicalTrials.gov ↗ · Obesity or Overweight
Phase 1 Recruiting 2025-11 China
Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes
NCT07527078 · ClinicalTrials.gov ↗ · Type 2 Diabetes (T2DM)
Phase 3 Recruiting 2026-04 China
Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss
NCT07292441 · ClinicalTrials.gov ↗ · Overweight or Obesity
Drug: GZR18
Phase 3 Recruiting 2026-01 China
A Phase 1 Study of GZC8072 Tablets Following a Single Dose in Healthy Study Participants and Multiple Doses in Obese/Overweight Study Participants
NCT07784699 · ClinicalTrials.gov ↗ · Healthy Subjects;Overweight or Obesity
Phase 1 Not yet open 2026-09 China
Bioequivalence Study of GZR4 Injection With Different Manufacturing Processes in Healthy Adult Participants
NCT07670897 · ClinicalTrials.gov ↗ · T2D
Phase 1 Not yet open 2026-07 China
Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes
NCT07387003 · ClinicalTrials.gov ↗ · Type 2 Diabetes (T2DM)
Drug: GZR33
Phase 2 Not yet open 2026-04 China
A Phase I Study to Evaluate the PK and PD Profiles of GZR102 Injection Versus GZR4 Injection and GZR18 Injection Given Separately in Chinese Adult Overweight Subjects
NCT06974487 · ClinicalTrials.gov ↗ · Type 2 Diabetes
Drugs: GZR102, GZR18, GZR4
Phase 1 Not yet open 2025-05 China
Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Receiving Positive Airway Pressure (PAP) Therapy
NCT07501832 · ClinicalTrials.gov ↗ · Obstructive Sleep Apnea (OSA)
Drug: GZR18
Phase 3 Not yet open 2026-03 China
A Phase I Clinical Study of GLR2037 in Patients With Advanced Prostate Cancer
NCT07468396 · ClinicalTrials.gov ↗ · Prostate Cancer
Phase 1 Not yet open 2026-04 China
A Study to Evaluate the Biosimilarity of GLR1044 Injection and Dupilumab Injection (Dupixent®) in Healthy Adult Male Subjects
NCT07334496 · ClinicalTrials.gov ↗ · Biosimilarity
Drug: Dupilumab
Phase 1 Not yet open 2026-03 China
Evaluate the Efficacy and Safety of GZR18 Injection in Obese Subjects With Obstructive Sleep Apnea Not Treated With Positive Airway Pressure (PAP) Therapy
NCT07493057 · ClinicalTrials.gov ↗ · Obstructive Sleep Apnea (OSA)
Drug: GZR18
Phase 3 Not yet open 2026-04 China
A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes Mellitus
NCT07055386 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus (T2DM)
Drugs: GZR102, GZR18
Phase 2 Active, closed 2025-08 China
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus
NCT06778967 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus (T2DM)
Phase 3 Active, closed 2025-02 China
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects
NCT06728124 · ClinicalTrials.gov ↗ · Obesity/Overweight
Drug: GZR18
Phase 3 Active, closed 2024-12 China
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Insulin-naive Subjects With Type 2 Diabetes Mellitus (T2DM)
NCT06767735 · ClinicalTrials.gov ↗ · Diabetes
Phase 3 Active, closed 2025-02 China
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise
NCT06777238 · ClinicalTrials.gov ↗ · Type 2 Diabetes Mellitus (T2DM)
Drug: GZR18
Phase 3 Active, closed 2025-01 China
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Type 2 Diabetes Mellitus Subjects (T2DM) Treated With Basal + Prandial Insulin
NCT06767761 · ClinicalTrials.gov ↗ · Diabetes
Drug: GZR4
Phase 3 Active, closed 2025-02 China
A Phase III Clinical Study to Assess the Efficacy and Safety of GZR4 in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin
NCT06767748 · ClinicalTrials.gov ↗ · Diabetes
Phase 3 Active, closed 2025-02 China
Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Hepatic Impairment
NCT07193147 · ClinicalTrials.gov ↗ · Diabetes
Drug: GZR4
Phase 1 Active, closed 2025-10 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Gan & Lee Pharmaceuticals trials

8 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Gan & Lee Pharmaceuticals trials

15 conditions
Diabetes5Type 2 Diabetes Mellitus (T2DM)3Obesity/Overweight3Type 2 Diabetes (T2DM)2Obstructive Sleep Apnea (OSA)2Healthy Subjects;Overweight or Obesity1Obesity&T2D1T2D1Primary Hyperlipidemia1Type 2 Diabetes1Obesity/Overweight in Adult1Obesity or Overweight1Prostate Cancer1Biosimilarity1Overweight or Obesity1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China259

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Diabetes

SponsorTrials
Shanghai Changzheng Hospital3
Viome2
Senseonics2
DexCom1
Beijing Shijitan Hospital, Capital Medical University1
The 95th Hospital of Putian,Putian, Fujian, China1

Sponsors with the most current trials registered for this condition.

06

Questions about Gan & Lee Pharmaceuticals trials

How many clinical trials does Gan & Lee Pharmaceuticals sponsor?

Gan & Lee Pharmaceuticals is the lead sponsor of 25 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Gan & Lee Pharmaceuticals trials recruiting?

Yes. 9 of its 25 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Gan & Lee Pharmaceuticals testing?

Its current trials name 8 drugs and biologicals as interventions. The most frequent are GZR18 (11), GZR4 (5), GZR102 (2), GZR33 (2) and Insulin Degludec (2). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.